Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


03.09.2018

1 Am J Chin Med
1 Ann Diagn Pathol
1 Can Urol Assoc J
1 Cancer Lett
4 Cancer Treat Res
2 Curr Opin Urol
1 Drug Des Devel Ther
1 Eur Urol
2 Eur Urol Focus
1 Front Med (Lausanne)
1 Gan To Kagaku Ryoho
1 Histopathology
1 In Vivo
1 Int J Cancer
4 Int J Mol Sci
2 Int Urol Nephrol
1 J Biophotonics
1 J Cell Biochem
2 J Cell Physiol
1 J Gastrointest Oncol
1 Jpn J Clin Oncol
1 Pathol Oncol Res
2 Transplant Proc
1 World J Urol
1 Zhong Nan Da Xue Xue Bao Yi Xue Ban


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Chin Med

  1. WANG K, Tan SL, Lu Q, Xu R, et al
    Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer.
    Am J Chin Med. 2018 Aug 27:1-12. doi: 10.1142/S0192415X18500714.
    PubMed     Text format     Abstract available


    Ann Diagn Pathol

  2. FUS LP, Pihowicz P, Koperski L, Marczewska JM, et al
    High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma.
    Ann Diagn Pathol. 2018;33:40-44.
    PubMed     Text format     Abstract available


    Can Urol Assoc J

  3. ASHE CG, Bagnell S, Gray S
    Images - Isolated forearm soft tissue metastasis from bladder cancer.
    Can Urol Assoc J. 2018 Aug 30. pii: cuaj.5341. doi: 10.5489/cuaj.5341.
    PubMed     Text format    


    Cancer Lett

  4. JUNG JH, You S, Oh JW, Yoon J, et al
    Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
    Cancer Lett. 2018 Aug 23. pii: S0304-3835(18)30526.
    PubMed     Text format     Abstract available


    Cancer Treat Res

  5. KISS B, Marcq G, Liao JC
    Optical and Cross-Sectional Imaging Technologies for Bladder Cancer.
    Cancer Treat Res. 2018;175:139-163.
    PubMed     Text format     Abstract available

  6. MITRA AP, Daneshmand S
    Molecular Prognostication in Bladder Cancer.
    Cancer Treat Res. 2018;175:165-191.
    PubMed     Text format     Abstract available

  7. LEE DJ, Chang SS
    The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer.
    Cancer Treat Res. 2018;175:193-214.
    PubMed     Text format     Abstract available

  8. RODRIGUEZ-VIDA A, Lerner SP, Bellmunt J
    The Cancer Genome Atlas Project in Bladder Cancer.
    Cancer Treat Res. 2018;175:259-271.
    PubMed     Text format     Abstract available


    Curr Opin Urol

  9. SORIA F, D'Andrea D, Pohar K, Shariat SF, et al
    Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?
    Curr Opin Urol. 2018 Aug 27. doi: 10.1097/MOU.0000000000000545.
    PubMed     Text format     Abstract available

  10. MANNAS MP, Lee T, Nykopp TK, Costa JBD, et al
    A risk-stratified approach to the management of high-grade T1 bladder cancer.
    Curr Opin Urol. 2018 Aug 24. doi: 10.1097/MOU.0000000000000548.
    PubMed     Text format     Abstract available


    Drug Des Devel Ther

  11. FAIENA I, Cummings AL, Crosetti AM, Pantuck AJ, et al
    Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
    Drug Des Devel Ther. 2018;12:209-215.
    PubMed     Text format     Abstract available


    Eur Urol

  12. LINARES-ESPINOS E, Sanchez-Salas R
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 22. pii: S0302-2838(18)30562.
    PubMed     Text format    


    Eur Urol Focus

  13. RAILKAR R, Agarwal PK
    Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations.
    Eur Urol Focus. 2018 Aug 22. pii: S2405-4569(18)30224.
    PubMed     Text format     Abstract available

  14. PSUTKA SP, Porten S
    Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape.
    Eur Urol Focus. 2018 Aug 25. pii: S2405-4569(18)30227.
    PubMed     Text format    


    Front Med (Lausanne)

  15. ISHIDA K, Hsieh MH
    Understanding Urogenital Schistosomiasis-Related Bladder Cancer: An Update.
    Front Med (Lausanne). 2018;5:223.
    PubMed     Text format     Abstract available


    Gan To Kagaku Ryoho

  16. FUKUHARA H, Inoue K
    [Navigation Surgery for Bladder Cancer by ALA-PDD].
    Gan To Kagaku Ryoho. 2018;45:1144-1146.
    PubMed     Text format     Abstract available


    Histopathology

  17. WANG CC, Huang CY, Jhuang YL, Chen CC, et al
    Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Histopathology. 2018;72:795-803.
    PubMed     Text format     Abstract available


    In Vivo

  18. DUSKOVA K, Vesely S, DO Carmo Silva J, Cernei N, et al
    Differences in Urinary Amino Acid Patterns in Individuals with Different Types of Urological Tumor Urinary Amino Acid Patterns as Markers of Urological Tumors.
    In Vivo. 2018;32:425-429.
    PubMed     Text format     Abstract available


    Int J Cancer

  19. HERMANS TJN, Voskuilen CS, Deelen M, Mertens LS, et al
    Superior Efficacy of Neoadjuvant Chemotherapy and Radical Cystectomy in cT3-4aN0M0 compared to cT2N0M0 Bladder Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31833.
    PubMed     Text format    


    Int J Mol Sci

  20. CHI H, Yang R, Zheng X, Zhang L, et al
    LncRNA RP11-79H23.3 Functions as a Competing Endogenous RNA to Regulate PTEN Expression through Sponging hsa-miR-107 in the Development of Bladder Cancer.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available

  21. GEELVINK M, Babmorad A, Maurer A, Stohr R, et al
    Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available

  22. TAN MP, Attard G, Huddart RA
    Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available

  23. LODEWIJK I, Duenas M, Rubio C, Munera-Maravilla E, et al
    Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available


    Int Urol Nephrol

  24. WANG Z, Li C, Jiang M, Chen J, et al
    Filamin A (FLNA) regulates autophagy of bladder carcinoma cell and affects its proliferation, invasion and metastasis.
    Int Urol Nephrol. 2018;50:263-273.
    PubMed     Text format     Abstract available

  25. MARUF M, Sidana A, Purnell S, Jain AL, et al
    Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database.
    Int Urol Nephrol. 2018;50:257-262.
    PubMed     Text format     Abstract available


    J Biophotonics

  26. ZHU S, Corsetti S, Wang Q, Li C, et al
    Optical sensory arrays for the detection of urinary bladder cancer related volatile organic compounds (VOCs).
    J Biophotonics. 2018 Aug 31:e201800165. doi: 10.1002/jbio.201800165.
    PubMed     Text format     Abstract available


    J Cell Biochem

  27. WANG C, Tao W, Ni S, Chen Q, et al
    Upregulation of lncRNA snoRNA host gene 6 regulates NUAK family SnF1-like kinase-1 expression by competitively binding microRNA-125b and interacting with Snail1/2 in bladder cancer.
    J Cell Biochem. 2018 Aug 30. doi: 10.1002/jcb.27387.
    PubMed     Text format     Abstract available


    J Cell Physiol

  28. ZHANG Z, Liu Y, Wang K, Zhu K, et al
    Activation of type 4 metabotropic glutamate receptor promotes cell apoptosis and inhibits proliferation in bladder cancer.
    J Cell Physiol. 2018 Aug 26. doi: 10.1002/jcp.27089.
    PubMed     Text format     Abstract available

  29. ZENG Z, Zhou W, Duan L, Zhang J, et al
    Circular RNA circ-VANGL1 as a competing endogenous RNA contributes to bladder cancer progression by regulating miR-605-3p/VANGL1 pathway.
    J Cell Physiol. 2018 Aug 26. doi: 10.1002/jcp.27162.
    PubMed     Text format     Abstract available


    J Gastrointest Oncol

  30. FAREED MM, DeMora L, Esnaola NF, Denlinger CS, et al
    Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas.
    J Gastrointest Oncol. 2018;9:762-768.
    PubMed     Text format     Abstract available


    Jpn J Clin Oncol

  31. OKABE K, Shindo T, Maehana T, Nishiyama N, et al
    Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
    Jpn J Clin Oncol. 2018 Aug 28. pii: 5085500. doi: 10.1093.
    PubMed     Text format     Abstract available


    Pathol Oncol Res

  32. EL-GENDI S, Abu-Sheasha G
    Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.
    Pathol Oncol Res. 2018;24:309-322.
    PubMed     Text format     Abstract available


    Transplant Proc

  33. HUANG GL, Luo HL, Chen YT, Cheng YT, et al
    Oncologic Outcomes of Post-Kidney Transplantation Superficial Urothelial Carcinoma.
    Transplant Proc. 2018;50:998-1000.
    PubMed     Text format     Abstract available

  34. KIDO K, Hatakeyama S, Hamano I, Yamamoto H, et al
    Partial Cystectomy of Paraganglioma of the Urinary Bladder Before Living Kidney Transplantation: Case Report.
    Transplant Proc. 2018;50:898-901.
    PubMed     Text format     Abstract available


    World J Urol

  35. ROUPRET M
    Immunotherapy for bladder cancer: the fight is on.
    World J Urol. 2018 Aug 30. pii: 10.1007/s00345-018-2468.
    PubMed     Text format    


    Zhong Nan Da Xue Xue Bao Yi Xue Ban

  36. LI B, Li Y
    [Comprehensive therapy of bladder preservation for muscle invasive bladder cancer].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018;43:82-89.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: